ALK is an inclusion eligibility criterion in 2 clinical trials for angioimmunoblastic T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

BIRC2 is an inclusion eligibility criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC2 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BIRC3 is an inclusion eligibility criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CARD11 is altered in 1.35% of angioimmunoblastic T-cell lymphoma patients [2].

CARD11 is an inclusion eligibility criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79A is an inclusion eligibility criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79A status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79B is an inclusion eligibility criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH2 is altered in 14.67% of angioimmunoblastic T-cell lymphoma patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

NFKBIA is an inclusion eligibility criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NFKBIA status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TNFAIP3 is altered in 2.7% of angioimmunoblastic T-cell lymphoma patients [2].

TNFAIP3 is an inclusion eligibility criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TNFAIP3 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].